- Report
- August 2025
- 196 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 197 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 196 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- August 2025
- 184 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 189 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 184 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- October 2025
- 181 Pages
Global
From €3151EUR$3,545USD£2,735GBP
€3501EUR$3,939USD£3,039GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Report
- May 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Report
- March 2025
- 200 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Report
- January 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Report
- September 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,464GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1333EUR$1,500USD£1,157GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1333EUR$1,500USD£1,157GBP
- Report
- August 2025
- 116 Pages
Global
From €2666EUR$2,999USD£2,314GBP
- Report
- January 2025
- 182 Pages
Global
From €4000EUR$4,500USD£3,472GBP
- Report
- July 2025
- 350 Pages
Global
From €4399EUR$4,949USD£3,818GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2479EUR$2,789USD£2,152GBP
- Report
- June 2024
- 200 Pages
Global
From €7067EUR$7,950USD£6,134GBP

Ezetimibe is a cholesterol-lowering drug used to treat high cholesterol and other lipid disorders. It works by reducing the absorption of cholesterol from the intestine, thereby reducing the amount of cholesterol in the blood. Ezetimibe is often used in combination with statins, another type of cholesterol-lowering drug, to further reduce cholesterol levels. It is also used to reduce the risk of cardiovascular events, such as heart attack and stroke, in people with existing cardiovascular disease.
Ezetimibe is a relatively new drug, having been approved by the US Food and Drug Administration in 2002. It is now widely used in the treatment of high cholesterol and other lipid disorders, and is increasingly being used in combination with statins to further reduce cholesterol levels.
Ezetimibe is marketed by several pharmaceutical companies, including Merck, Pfizer, Sanofi, and Daiichi Sankyo. It is also available in generic form from several generic drug manufacturers. Show Less Read more